SG11201701035SA - Cancer diagnosis and therapy - Google Patents
Cancer diagnosis and therapyInfo
- Publication number
- SG11201701035SA SG11201701035SA SG11201701035SA SG11201701035SA SG11201701035SA SG 11201701035S A SG11201701035S A SG 11201701035SA SG 11201701035S A SG11201701035S A SG 11201701035SA SG 11201701035S A SG11201701035S A SG 11201701035SA SG 11201701035S A SG11201701035S A SG 11201701035SA
- Authority
- SG
- Singapore
- Prior art keywords
- therapy
- cancer diagnosis
- diagnosis
- cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462036583P | 2014-08-12 | 2014-08-12 | |
| PCT/NZ2015/050108 WO2016024870A1 (en) | 2014-08-12 | 2015-08-12 | Cancer diagnosis and therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701035SA true SG11201701035SA (en) | 2017-03-30 |
Family
ID=55304402
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201901157QA SG10201901157QA (en) | 2014-08-12 | 2015-08-12 | Cancer diagnosis and therapy |
| SG11201701035SA SG11201701035SA (en) | 2014-08-12 | 2015-08-12 | Cancer diagnosis and therapy |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201901157QA SG10201901157QA (en) | 2014-08-12 | 2015-08-12 | Cancer diagnosis and therapy |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10281472B2 (en) |
| EP (1) | EP3180000A4 (en) |
| JP (1) | JP6899771B2 (en) |
| KR (1) | KR20170040804A (en) |
| CN (1) | CN106999471A (en) |
| AU (1) | AU2015302419B2 (en) |
| BR (1) | BR112017002724A2 (en) |
| CA (1) | CA2957930A1 (en) |
| CL (1) | CL2017000373A1 (en) |
| MX (1) | MX2017001954A (en) |
| SG (2) | SG10201901157QA (en) |
| WO (1) | WO2016024870A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016364623A1 (en) * | 2015-11-30 | 2018-05-31 | Gillies Mcindoe Research Institute | Treatment of fibrotic conditions |
| US20170360829A1 (en) * | 2016-01-27 | 2017-12-21 | Gillies Mcindoe Research Institute | Treatment of vascular anomalies |
| WO2017207656A1 (en) * | 2016-05-31 | 2017-12-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Atp6ap2 inhibition for treating or preventing a tumoural and/or proliferative disorder of the central nervous system |
| JP2020515523A (en) * | 2017-01-31 | 2020-05-28 | ギリース・マッキンドー・リサーチ・インスティチュートＧｉｌｌｉｅｓ Ｍｃｉｎｄｏｅ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | Cancer treatment |
| WO2019079222A1 (en) | 2017-10-16 | 2019-04-25 | Board Of Regents Of The University Of Texas System | Compositions for inhibiting 3' repair exonuclease 2 and methods of screening for such compositions |
| US10882915B2 (en) * | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
| WO2020027665A1 (en) * | 2018-07-30 | 2020-02-06 | Gillies Mcindoe Research Institute | Novel pharmaceutical compositions for cancer therapy |
| WO2020028007A1 (en) * | 2018-07-31 | 2020-02-06 | Colorado State University Research Foundation | Compositions, methods and uses for modulating the tumor microenvironment to enhance antitumor immunity |
| CN111304324B (en) * | 2020-02-21 | 2021-05-14 | 温州医科大学 | Application of ALPL gene as diagnosis and treatment target of lung adenocarcinoma and lung adenocarcinoma metastasis |
| CA3177987A1 (en) * | 2020-05-08 | 2021-11-11 | Ashish Tripathi | Methods for identifying a medical condition in a human subject |
| CN113069443A (en) * | 2021-04-12 | 2021-07-06 | 四川大学 | Application of nebivolol in preparation of medicine for preventing and/or treating oral leukoplakia and oral squamous cell carcinoma |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4121547A1 (en) | 1991-06-28 | 1993-01-14 | Daimler Benz Ag | MULTILAYER INSULATION FILM |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US7361336B1 (en) | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
| US6004528A (en) | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
| US6946475B1 (en) * | 1999-04-07 | 2005-09-20 | University Of Virginia Patent Foundation | Anticancer calcium channel blockers |
| JP2004509835A (en) | 2000-03-06 | 2004-04-02 | ユニヴァーシティ オブ ケンタッキー リサーチ ファンデーション | Methods of damaging hematologic cancer progenitor cells and related compounds |
| US6605589B1 (en) * | 2000-03-31 | 2003-08-12 | Parker Hughes Institute | Cathepsin inhibitors in cancer treatment |
| WO2002098370A2 (en) | 2001-03-02 | 2002-12-12 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
| US6632832B1 (en) * | 2002-09-10 | 2003-10-14 | Dabur Research Foundation | Anti-cancer activity of carvedilol and its isomers |
| US7354584B2 (en) | 2003-04-11 | 2008-04-08 | Medimmune, Inc. | Recombinant IL-9 antibodies |
| WO2010030500A1 (en) * | 2008-09-09 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Aza-benzimidazolone chymase inhibitors |
| US8541544B2 (en) * | 2008-10-27 | 2013-09-24 | Dainippon Sumitomo Pharma Co., Ltd. | Molecular marker for cancer stem cell |
| WO2012030234A1 (en) * | 2010-09-01 | 2012-03-08 | Swee Thong Tan | Methods and compositions for treating cancer |
| WO2013188715A2 (en) * | 2012-06-13 | 2013-12-19 | Herr John C | Compositions and methods for treating cancer |
| AU2014281464B2 (en) * | 2013-06-19 | 2019-09-26 | University Of Miami | Classification system, methods and kit for classifying, predicting and treating breast cancer |
-
2015
- 2015-08-12 MX MX2017001954A patent/MX2017001954A/en unknown
- 2015-08-12 CN CN201580056218.1A patent/CN106999471A/en active Pending
- 2015-08-12 WO PCT/NZ2015/050108 patent/WO2016024870A1/en active Application Filing
- 2015-08-12 SG SG10201901157QA patent/SG10201901157QA/en unknown
- 2015-08-12 EP EP15832111.7A patent/EP3180000A4/en not_active Withdrawn
- 2015-08-12 BR BR112017002724A patent/BR112017002724A2/en not_active IP Right Cessation
- 2015-08-12 JP JP2017528398A patent/JP6899771B2/en active Active
- 2015-08-12 KR KR1020177006765A patent/KR20170040804A/en unknown
- 2015-08-12 US US15/503,025 patent/US10281472B2/en active Active
- 2015-08-12 AU AU2015302419A patent/AU2015302419B2/en active Active
- 2015-08-12 SG SG11201701035SA patent/SG11201701035SA/en unknown
- 2015-08-12 CA CA2957930A patent/CA2957930A1/en active Pending
-
2017
- 2017-02-13 CL CL2017000373A patent/CL2017000373A1/en unknown
-
2019
- 2019-03-04 US US16/291,716 patent/US20200041521A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017532368A (en) | 2017-11-02 |
| US20170234884A1 (en) | 2017-08-17 |
| AU2015302419A1 (en) | 2017-03-09 |
| JP6899771B2 (en) | 2021-07-14 |
| CN106999471A (en) | 2017-08-01 |
| EP3180000A4 (en) | 2018-03-07 |
| BR112017002724A2 (en) | 2018-01-16 |
| EP3180000A1 (en) | 2017-06-21 |
| US10281472B2 (en) | 2019-05-07 |
| MX2017001954A (en) | 2017-08-14 |
| CA2957930A1 (en) | 2016-02-18 |
| SG10201901157QA (en) | 2019-03-28 |
| KR20170040804A (en) | 2017-04-13 |
| US20200041521A1 (en) | 2020-02-06 |
| CL2017000373A1 (en) | 2018-01-12 |
| AU2015302419B2 (en) | 2021-04-01 |
| WO2016024870A1 (en) | 2016-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1248773A1 (en) | Therapeutic and diagnostic methods for cancer | |
| HK1250376A1 (en) | Therapeutic and diagnostic methods for cancer | |
| SG11201701035SA (en) | Cancer diagnosis and therapy | |
| GB201409363D0 (en) | Skin cancer treatment | |
| GB201401806D0 (en) | Novel methods for diagnosis and therapy | |
| GB201411884D0 (en) | Cancer therapy | |
| GB201404508D0 (en) | Therapeutic and diagnostic target | |
| GB201404500D0 (en) | Therapeutic and diagnostic target | |
| GB201404132D0 (en) | Therapeutic and diagnostic target | |
| GB201404150D0 (en) | Therapeutic and diagnostic target | |
| GB201404135D0 (en) | Therapeutic and diagnostic target | |
| GB201404137D0 (en) | Therapeutic and diagnostic target | |
| GB201404082D0 (en) | Therapeutic and diagnostic target | |
| GB201404087D0 (en) | Therapeutic and diagnostic target | |
| GB201403965D0 (en) | Therapeutic and diagnostic target | |
| GB201403930D0 (en) | Therapeutic and diagnostic target | |
| GB201403958D0 (en) | Therapeutic and diagnostic target | |
| GB201403446D0 (en) | Therapeutic and diagnostic target | |
| GB201403450D0 (en) | Therapeutic and diagnostic target | |
| GB201403492D0 (en) | Therapeutic and diagnostic target | |
| GB201403390D0 (en) | Therapeutic and diagnostic target | |
| GB201403367D0 (en) | Therapeutic and diagnostic target | |
| GB201403368D0 (en) | Therapeutic and diagnostic target | |
| GB201403387D0 (en) | Therapeutic and diagnostic target | |
| GB201403364D0 (en) | Therapeutic and diagnostic target |